SMA

SMA
Name	Spinal muscular atrophy
Caption	Motor neuron loss in anterior horn
Specialty	Neurology
Symptoms	Progressive muscle weakness, hypotonia, respiratory failure
Onset	Infancy to adulthood
Causes	Bi-allelic deletion or mutation in SMN1
Diagnosis	Genetic testing, electromyography
Treatment	Nusinersen, onasemnogene abeparvovec, risdiplam, supportive care
Prognosis	Variable; improved with disease-modifying therapies

SMA

Spinal muscular atrophy is a hereditary neuromuscular disease caused by loss of motor neurons in the anterior horn of the spinal cord, leading to progressive proximal muscle weakness and atrophy. It classically presents across a spectrum from severe infantile forms to milder adult-onset phenotypes and has been a focus of genetic discovery, newborn screening, and targeted molecular therapies developed in recent decades. Landmark court cases, regulatory approvals, and international newborn screening programs have reshaped clinical care and research priorities.

Medical overview

Spinal muscular atrophy is characterized by degeneration of lower motor neurons in the Spinal cord, resulting in flaccid paralysis and respiratory compromise that historically led to early mortality in Infant forms. The clinical spectrum ranges from severe hypotonia with feeding and breathing failure in infants—historically managed in specialized centers such as Great Ormond Street Hospital and subject to discussions in Bioethics literature—to ambulatory adult forms managed in multidisciplinary clinics aligned with standards from organizations like the American Academy of Neurology and European Neuromuscular Centre. Advances in rehabilitative approaches pioneered at institutions such as Shriners Hospitals for Children and respiratory protocols influenced by Paediatric Intensive Care Unit practice have changed natural history.

Genetics and pathophysiology

SMA arises from homozygous deletion or mutation of the survival motor neuron 1 gene located on chromosome 5q, with disease-modifying effects attributable to copy number variation in the paralogous survival motor neuron 2 gene. The molecular genetics were elucidated in seminal studies involving teams at Cold Spring Harbor Laboratory and University of Massachusetts Medical School, with contributions from investigators affiliated with Genzyme and Biogen during therapeutic development. Loss of SMN1 causes reduced SMN protein, impairing snRNP assembly and axonal transport mechanisms studied in model systems at Max Planck Institute and Massachusetts Institute of Technology. Modifier genes, mitochondrial pathways, and ubiquitin-proteasome interactions investigated at centers such as Broad Institute and Johns Hopkins University further refine phenotype. Genetic testing using methods developed by commercial laboratories including Mayo Clinic Laboratories and ARUP Laboratories permits carrier detection, prenatal diagnosis, and newborn screening recommended by panels like the Advisory Committee on Heritable Disorders in Newborns and Children.

Clinical presentation and diagnosis

Infantile-onset presentations typically show profound hypotonia, absent deep tendon reflexes, poor suck and cry, and respiratory insufficiency leading to hospitalization in neonatal units such as Neonatal Intensive Care Units affiliated with Boston Children's Hospital. Later-onset forms present with progressive proximal weakness, scoliosis, and orthopaedic complications managed by teams at Shriners Hospitals for Children and Great Ormond Street Hospital. Diagnostic evaluation combines electrophysiology (electromyography), neuroimaging performed at centers like Mayo Clinic, and definitive molecular testing undertaken by laboratories such as Quest Diagnostics. Clinical scales developed in multicenter studies coordinated by organizations including TREAT-NMD and the International SMA Consortium guide severity stratification and outcome measures used in trials.

Management and treatment

Management integrates disease-modifying therapies with supportive multidisciplinary care. The first approved therapies—antisense oligonucleotide therapy delivered intrathecally and gene replacement therapy administered systemically—were developed and commercialized by companies such as Biogen, Novartis, and Roche following regulatory approvals by agencies including the U.S. Food and Drug Administration and the European Medicines Agency. Small-molecule oral modulators approved after pivotal trials conducted at academic centers like Columbia University Irving Medical Center complement treatment options. Supportive measures for nutrition, respiratory support, and orthopaedics follow protocols from societies such as the American Thoracic Society and European Respiratory Society and involve collaboration with physical therapy programs at institutions like University of California, San Francisco. Newborn screening initiatives in jurisdictions such as Newborn Screening Ontario and pilot programs in United Kingdom regions enable presymptomatic treatment, altering outcomes reported in registries maintained by organizations like SMA Foundation and Parent Project Muscular Dystrophy.

Epidemiology and prognosis

Population studies conducted in regions including Scandinavia, United States, and Japan indicate an incidence of approximately 1 in 6,000 to 1 in 10,000 live births for severe forms, with carrier frequencies varying by population and catalogued in databases such as gnomAD and registries curated by Orphanet. Prognosis has improved substantially with early treatment documented in cohort studies from Duke University and Hospital for Sick Children (Toronto), shifting survival and motor milestone attainment compared to historical cohorts described at Johns Hopkins Hospital and in classic literature from the 1950s and 1960s.

Research and emerging therapies

Current research spans gene editing, novel small molecules, neuroprotective agents, and biomarkers validated in multicenter consortia including NIH-funded networks and collaborations involving Cincinnati Children's Hospital Medical Center, University College London, and industry partners like Pfizer and Roche. Trials employing CRISPR-based strategies, antisense optimization, and combination regimens are underway at investigational centers such as Massachusetts General Hospital and monitored by regulators including the FDA and European Medicines Agency. Natural history studies and real-world evidence collected by global registries coordinated with groups like TREAT-NMD continue to inform newborn screening policies, health technology assessments, and long-term outcomes reported in journals such as The Lancet and Neurology.

Category:Neuromuscular disorders